Annual Accounts Receivable
$1.70 M
+$1.64 M+2878.95%
December 31, 2023
Summary
- As of February 20, 2025, CUE annual accounts receivable is $1.70 million, with the most recent change of +$1.64 million (+2878.95%) on December 31, 2023.
- During the last 3 years, CUE annual accounts receivable has risen by +$280.50 thousand (+19.79%).
- CUE annual accounts receivable is now -45.97% below its all-time high of $3.14 million, reached on December 31, 2021.
Performance
CUE Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$3.15 M
+$1.30 M+70.66%
September 30, 2024
Summary
- As of February 20, 2025, CUE quarterly accounts receivable is $3.15 million, with the most recent change of +$1.30 million (+70.66%) on September 30, 2024.
- Over the past year, CUE quarterly accounts receivable has increased by +$1.30 million (+70.66%).
- CUE quarterly accounts receivable is now at all-time high.
Performance
CUE Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CUE Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2878.9% | +70.7% |
| 3 y3 years | +19.8% | +5429.8% |
| 5 y5 years | +100.0% | +5429.8% |
CUE Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -46.0% | +2878.9% | at high | +5429.8% |
| 5 y | 5-year | -46.0% | +2878.9% | at high | +5429.8% |
| alltime | all time | -46.0% | -100.0% | at high | -100.0% |
Cue Biopharma Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.15 M(+70.7%) |
| Jun 2024 | - | $1.85 M(+31.9%) |
| Mar 2024 | - | $1.40 M(-17.6%) |
| Dec 2023 | $1.70 M(+2878.9%) | $1.70 M(+2.2%) |
| Sep 2023 | - | $1.66 M(+46.3%) |
| Jun 2023 | - | $1.14 M(+479.1%) |
| Mar 2023 | - | $196.00 K(+243.9%) |
| Dec 2022 | $57.00 K(-98.2%) | $57.00 K(-92.8%) |
| Sep 2022 | - | $796.00 K(+8.2%) |
| Jun 2022 | - | $736.00 K(-20.4%) |
| Mar 2022 | - | $925.00 K(-70.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $3.14 M(+121.7%) | $3.14 M(+307.6%) |
| Sep 2021 | - | $771.00 K(-59.5%) |
| Jun 2021 | - | $1.90 M(+34.7%) |
| Mar 2021 | - | $1.41 M(-0.3%) |
| Dec 2020 | $1.42 M(+87.8%) | $1.42 M(+210.2%) |
| Sep 2020 | - | $457.00 K(-62.8%) |
| Jun 2020 | - | $1.23 M(+103.0%) |
| Mar 2020 | - | $605.00 K(-19.9%) |
| Dec 2019 | $754.90 K(>+9900.0%) | $754.90 K(+23.8%) |
| Sep 2019 | - | $610.00 K(+16.9%) |
| Jun 2019 | - | $522.00 K(>+9900.0%) |
| Dec 2018 | $0.00 | $0.00 |
FAQ
- What is Cue Biopharma annual accounts receivable?
- What is the all time high annual accounts receivable for Cue Biopharma?
- What is Cue Biopharma annual accounts receivable year-on-year change?
- What is Cue Biopharma quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Cue Biopharma?
- What is Cue Biopharma quarterly accounts receivable year-on-year change?
What is Cue Biopharma annual accounts receivable?
The current annual accounts receivable of CUE is $1.70 M
What is the all time high annual accounts receivable for Cue Biopharma?
Cue Biopharma all-time high annual accounts receivable is $3.14 M
What is Cue Biopharma annual accounts receivable year-on-year change?
Over the past year, CUE annual accounts receivable has changed by +$1.64 M (+2878.95%)
What is Cue Biopharma quarterly accounts receivable?
The current quarterly accounts receivable of CUE is $3.15 M
What is the all time high quarterly accounts receivable for Cue Biopharma?
Cue Biopharma all-time high quarterly accounts receivable is $3.15 M
What is Cue Biopharma quarterly accounts receivable year-on-year change?
Over the past year, CUE quarterly accounts receivable has changed by +$1.30 M (+70.66%)